Medialis Intelligent End-to-End Medical Affairs
Medialis has full CRO capabilities as well a RWE and data synthesis expertise. This enables Medialis to deliver each and every RWE ‘asset’ we design for our clients.scroll down
Medical Affairs Strategies for Real-World Evidence Generation
The benefits of being able to both design and deliver the same key evidence?
It ensures the asset remains true to its design and ensures it meets its desired objectives.
Furthermore, generating a piece of RWE is only half the story. The appropriate KOLs need to be engaged in any asset’s delivery.
Medialis can map external experts in a given therapy area and engage with them on a peer-to-peer level to optimise the delivery of each piece of key evidence…
After assets are configured…
A decision needs to be made as to which external experts (or KOLs) the organisation will work with to generate the assets.
Each asset will require experts to be selected on the basis of their experience and interest.
Medialis will work with you to select the appropriate experts
Medialis will work with its client to map the external experts in the therapy area and select those most appropriate to participate in each asset generation.
Real-World Patients need Real-World Evidence
We are a patient-focussed medical affairs company dedicated to ensuring that patients’ voices are heard through the generation of key Real-World Evidence.
Some lessons learned from previous SWOT analysis:
The overall SWOT exercise demonstrated a significant degree of variation in items perceived as Strengths, Weaknesses, Opportunities and Threats
The Method enabled participants to reach consensus on the inclusion of these items in the final CSF list
The conversion of the SWOT observations to interventional CSFs, therefore, reached complete approval
All CSF’s were advanced to the final stage to formulate Aspirational Statements
Medialis conducted background research on the proposed aspirations and included a summary of recommendations for each in the final Medical Plan.
Medialis Medical Planning and the Multi-Stakeholder Approach
Learn how we can ensure that a medical plan is developed with the full engagement of all stakeholders.
Coordinating and collecting feedback in an efficient way to ensure the items included in the plan are agreed by the internal stakeholders can be a challenge.
Our approach involves using a novel group awareness and consensus methodology to generate and agree, the SWOT, Critical Success Factors (CSFs), Aspirational Statement before we go away and design the tactics themselves
Because we can deliver the optimal RWE generation for your products:
- Overview of the disease and global market trends for the G7 i.e., USA, EU5 (France, Germany, Italy, Spain, UK), and India.
- Attributes of therapeutic market revenue, algorithm or treatment practice and forecasted market size from 2019 to 2020 segmented by G7
- Epidemiology Forecast till 2020 for G7
- Attribute Analysis of prioritized drugs on the basis of Safety, Efficacy, and Route of Administration
- Market Access & Reimbursement strategy
- Key market drivers, market barriers, and unmet medical need
- A thorough analysis of the rate of uptake of the potential drugs, market uptake by drugs, patient uptake by therapies, sales of each drug